Stroke is defined by WHO as the clinical syndrome of rapid onset of focal (or global, as in
subarachnoid haemorrhage) cerebral deficits lasting more than 24 hours or leading to …

Stroke was defined by the World Health Organization (WHO) in 1970, as rapidly developing
clinical signs of focal (or global) cerebral deficits, with symptoms lasting 24 hours or longer …

Stroke is defined as a “neurological deficit attributed to an acute focal injury of the central
nervous system by a vascular cause”(2). Several types of stroke exist, depending on their …

Methylarginines have been shown to interfere with NO (nitric oxide) formation by inhibiting
NOS (NO synthase)–ADMA (asymmetric dimethylarginine) and cellular l-arginine uptake …

Background: Increased levels of asymmetric dimethylarginine (ADMA) and symmetric
dimethylarginine (SDMA) are associated with endothelial dysfunction. Here, we analyzed …

Background Endothelial dysfunction is associated with increased levels of asymmetric
dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) resulting in a decreased …

Abstract Background and Purpose: Serum S100B has been widely studied as a biomarker in
acute ischaemic stroke. The main objective of this review was to appraise the published …

Background and Purpose—Biochemical markers of acute neuronal injury may aid in the
diagnosis and management of acute ischemic stroke. Serum samples from the National …

OBJECTIVE: Methylarginines have been shown to interfere with nitric oxide (NO) formation
by inhibiting NO synthase (asymmetric dimethylarginine, ADMA, and monomethylarginine …

Background: Stroke is a devastating condition encompassing a wide range of
pathophysiological entities that include thrombosis, hemorrhage, and embolism. Current …